Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KMTS
KMTS logo

KMTS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kestra Medical Technologies Ltd (KMTS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
27.850
1 Day change
-0.11%
52 Week Range
30.000
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

KMTS is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock has positive momentum, but it is also overbought and lacks confirming signals from Intellectia, news flow, or recent institutional/insider activity. My direct view: hold off for now rather than buy immediately.

Technical Analysis

KMTS is in an uptrend, but the setup is stretched. MACD histogram is positive at 0.742 and expanding, which supports bullish momentum. However, RSI_6 is 81.885, which is clearly overbought and suggests the recent move may be extended. Moving averages are converging, which indicates the trend is still developing rather than cleanly established. Price at 26.99 is just above R1 at 26.927, so near-term resistance has already been tested. The next resistance is R2 at 29.079, while support is much lower at 23.443 pivot and 19.959 S1. With the stock already near resistance and technically overbought, the current price is not an attractive immediate long-term entry.

Positive Catalysts

  • BTIG reiterated a Buy rating and still sees upside with a $30 price target, which is above the current price. The company also has an upcoming earnings date on 2026-07-14, which could provide a catalyst if results or guidance are strong. The MACD expansion also confirms current bullish momentum.

Neutral/Negative Catalysts

  • No news in the recent week means there is no fresh catalyst supporting a new purchase. RSI is overbought, so the stock may be extended short term. Hedge funds and insiders are both neutral with no meaningful accumulation trend. AI Stock Picker has no signal today and SwingMax has no recent signal, removing the strongest proprietary buy confirmation. Congress trading data is unavailable, and the short-horizon pattern outlook is weak-to-mixed with negative weekly and monthly expectations.

Financial Performance

Financial snapshot data was unavailable due to an error, so there is no reliable latest-quarter revenue or earnings growth breakdown to support a fundamental buy decision. The only financial timing item provided is the upcoming Q2026Q4 earnings on 2026-07-14, which is the next key financial event to watch.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst sentiment is constructive but slightly less aggressive than before: BTIG lowered its target from $32 to $30 while keeping a Buy rating. That is still bullish, but the reduced target suggests some moderation in expectations. Wall Street’s pros: buy rating remains intact and target is above market price. Cons: target cut, no broad evidence of strong fresh upgrades, and no recent news or institutional buying to reinforce the view.

Wall Street analysts forecast KMTS stock price to rise
6 Analyst Rating
Wall Street analysts forecast KMTS stock price to rise
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.880
sliders
Low
27
Averages
29.5
High
32
Current: 27.880
sliders
Low
27
Averages
29.5
High
32
BTIG
Buy
downgrade
$32 -> $30
AI Analysis
2026-04-13
Reason
BTIG
Price Target
$32 -> $30
AI Analysis
2026-04-13
downgrade
Buy
Reason
BTIG lowered the firm's price target on Kestra Medical to $30 from $32 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Goldman Sachs
Neutral
downgrade
$27 -> $24
2026-01-16
Reason
Goldman Sachs
Price Target
$27 -> $24
2026-01-16
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Kestra Medical to $24 from $27 and keeps a Neutral rating on the shares. MedTech and Healthcare IT stocks fell sharply from January 8-14, declining about 3% and 11%, respectively, in a move that appears largely disconnected from fundamentals, the analyst tells investors in a research note. Even companies pre-announcing above-consensus results saw share weakness, despite forward outlooks generally at or above current Street expectations, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KMTS
Unlock Now

People Also Watch